×

Landmark NIH Genome Atlas Study Identifies Four Distinct Types of Breast Cancer

The Journal Nature recently published a ground breaking Genome Atlas cancer study identifying four genetically distinct types of breast cancer. NIH researchers found hallmark genetic changes are driving many cancers. These findings are expected to lead to new ideas for more precise treatments aimed at genetic mutations. Matthew Ellis, a researcher for the study, said "this is the road map for how we might cure breast cancer in the future."

WHAT:

Tumor-specific genomic sequencing and analysis is quickly becoming the standard of care in oncology and is available TODAY. Caris Target Now, an evidence-based molecular profiling service, provides patient-specific information to help physicians personalize cancer therapy based on the unique biomarkers found in a patient's tumor.



WHO:

Jenny C. Chang, MD, Director, Methodist Cancer Center, The Methodist Hospital in Houston, Texas, and Professor of Medicine, Weill Cornell Medical College of Cornell University




Sandeep Reddy, MD, Clinical Professor of Medicine, David Geffen School of Medicine at UCLA, and Senior Medical Director at Caris Life Sciences




Raheela Ashfaq, MD, Director of Oncologic Profiling at Caris Life Sciences



CONTACT:

To request an interview or additional details, contact: David Patti, (609) 514-5117 or dpatti@jfkhealth.com

About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on developing and delivering innovative molecular diagnostic, prognostic, and theranostic services. The company's evidence-based molecular profiling service, Caris Target Now™, matches molecular data generated from a patient's tumor with biomarker/drug associations derived from the world's leading clinical cancer literature. Caris Target Now uses the most advanced and clinically relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the company's proprietary Carisome™ platform — a proprietary, blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Through the precise and personalized information provided by technologies like Caris Target Now and Carisome, the company believes that the quality of healthcare can be dramatically improved, while also significantly reducing costs. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit www.carislifesciences.eu or www.caristargetnow.com.

CONTACT:
David Patti – JFK Communications
(609) 514-5117
dpatti@jfkhealth.com

/PRNewswire -- Oct. 2, 2012/

SOURCE Caris Life Sciences